Sign In
Buy IMNM
$22.76
-0.320 (-1.39%)
At Close: Jul 31, 2026
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:03pm, Thursday, 02'nd Jan 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced
3 Small-Cap Stocks With Big Growth Potential
07:01am, Friday, 13'th Dec 2024
According to several indicators—including a robust labor market and tamed inflation figures—the U.S. economy heads into 2025 with strong tailwinds. Many of the securities that have been primary be
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:26pm, Monday, 02'nd Dec 2024
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference
08:00am, Wednesday, 27'th Nov 2024
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome'
Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates
06:16pm, Wednesday, 13'th Nov 2024
Immunome, Inc. (IMNM) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.36 per share a year ago.
Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference
08:00am, Tuesday, 05'th Nov 2024
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Sieg
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 01'st Nov 2024
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
08:00am, Tuesday, 29'th Oct 2024
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented promising p
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will p
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Tuesday, 08'th Oct 2024
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
08:00am, Thursday, 29'th Aug 2024
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Sieg
Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates
06:15pm, Monday, 12'th Aug 2024
Immunome, Inc. (IMNM) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.46 per share a year ago.
Immunome: AL102 And Other Established Protein Targets Could Drive Value
02:14pm, Thursday, 27'th Jun 2024
Top-line data from Part B of phase 3 RINGSIDE study, using AL102 for the treatment of patients with desmoid tumors, expected 2nd half of 2025. The global desmoid tumor market is projected to grow to $
Immunome Announces Completion of Purchase of Assets from Atreca
08:00am, Monday, 20'th May 2024
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the completion
Immunome Announces Promotion of Max Rosett to Chief Financial Officer
08:00am, Friday, 17'th May 2024
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the promotion
